Pre-Approval Market Access
During clinical trials, patients may not be able to access a trial medicine either because they are ineligible for or don’t have access to the trial. Post clinical trials, a trial medicine may never make it to market or a patient may need to continue treatment until it does. TannerMAP works with biopharmaceutical companies to improve patient access to trial medicines.
Post-Approval Market Access
After clinical trials, a medicine may not be registered in a market for many years, or ever. Likewise, a medicine may be withdrawn from a market or suffer a supply disruption. If a medicine is available somewhere in the world, TannerMAP works with biopharmaceutical companies to help patients get access to it.
Some biopharmaceutical companies are working with non-profit organizations to provide free access to their medicines in countries where patients can’t afford them. TannerMAP works with these organizations to get medicines to patients in need across the globe.